2023 World Conference on Lung Cancer (Posters)-EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer

EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

The study presented in this abstract aimed to evaluate the efficacy of durvalumab consolidation therapy for patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), specifically focusing on its effectiveness in patients with driver mutations. Durvalumab is a standard treatment for patients with locally advanced NSCLC. The study included 141 patients who received definitive chemoradiotherapy at a single institution and were divided into two groups based on the approval period of durvalumab. The efficacy of durvalumab was measured by progression-free survival (PFS).<br /><br />The results showed that durvalumab consolidation therapy tended to improve median PFS compared to conventional watchful waiting strategy (664 days vs 377 days). When analyzing patients without driver mutations, durvalumab consolidation therapy showed a statistically longer median PFS compared to the conventional strategy (695 days vs 382 days). However, durvalumab consolidation did not demonstrate a PFS benefit for patients with driver mutations.<br /><br />The study noted that the proportion of patients with driver mutations was higher in their cohort (21.7%) compared to the PACIFIC trial (6.0%). Other research suggests that driver mutations might be associated with poor PFS response to durvalumab. The study highlights the need for further investigation and data accumulation to evaluate the efficacy and safety of durvalumab consolidation therapy for patients with driver mutations.<br /><br />The characteristics of the patient groups included in the study were also presented, including their age, gender, smoking history, ECOG-PS, histologic subtype, PD-L1 status, driver mutation status, and chemotherapy regimens.<br /><br />In conclusion, the study suggests that in their small cohort of locally advanced NSCLC patients with driver mutations, durvalumab consolidation therapy did not show a progression-free benefit over the conventional watchful waiting strategy. Further research is needed to understand the limited efficacy of durvalumab for patients with driver mutations.

Asset Subtitle

Yuki Akazawa

Meta Tag

Speaker Yuki Akazawa

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

durvalumab consolidation therapy

locally advanced non-small cell lung cancer

unresectable NSCLC

efficacy

driver mutations

progression-free survival

chemoradiotherapy

watchful waiting strategy

PACIFIC trial

safety